Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

G-EYE colonoscopy is superior to standard colonoscopy for increasing adenoma detection rate: an international randomized controlled trial (with videos).

Shirin H, Shpak B, Epshtein J, Karstensen JG, Hoffman A, de Ridder R, Testoni PA, Ishaq S, Reddy DN, Gross SA, Neumann H, Goetz M, Abramowich D, Moshkowitz M, Mizrahi M, Vilmann P, Rey JW, Sanduleanu-Dascalescu S, Viale E, Chaudhari H, Pochapin MB, Yair M, Shnell M, Yaari S, Hendel JW, Teubner D, Bogie RMM, Notaristefano C, Simantov R, Gluck N, Israeli E, Stigaard T, Matalon S, Vilkin A, Benson A, Sloth S, Maliar A, Waizbard A, Jacob H, Thielsen P, Shachar E, Rochberger S, Hershcovici T, Plougmann JI, Braverman M, Tsvang E, Abedi AA, Brachman Y, Siersema PD, Kiesslich R.

Gastrointest Endosc. 2019 Mar;89(3):545-553. doi: 10.1016/j.gie.2018.09.028. Epub 2018 Sep 28.

2.
3.

The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases.

Viteri Malone MA, Ares GR, De Velasco G, Brandão R, Lin X, Norton C, Simantov R, Moslehi J, Krajewski KM, Choueiri TK, McKay RR.

Clin Genitourin Cancer. 2018 Apr;16(2):e327-e333. doi: 10.1016/j.clgc.2017.11.005. Epub 2017 Dec 6.

PMID:
29361425
4.

Characterization of Patients With Poor-Risk Metastatic Renal-Cell Carcinoma: Results From a Pooled Clinical Trials Database.

Hamieh L, McKay RR, Lin X, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Aug 12. pii: S1558-7673(17)30231-8. doi: 10.1016/j.clgc.2017.07.021. [Epub ahead of print]

PMID:
28918175
5.

Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.

Lalani AA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):724-732. doi: 10.1016/j.clgc.2017.05.019. Epub 2017 May 31.

PMID:
28645482
6.

Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.

de Velasco G, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Dec;15(6):652-660.e1. doi: 10.1016/j.clgc.2017.03.004. Epub 2017 Mar 21.

PMID:
28410911
7.

Design and Rationale of the Metastatic Renal Cell Carcinoma (MaRCC) Registry: A Prospective Academic and Community-Based Study of Patients With Metastatic Renal Cell Cancer.

Bhavsar NA, Harrison MR, Hirsch BR, Creel P, Wolf SP, Samsa GP, Abernethy AP, Simantov R, Borham A, George DJ.

Cancer Invest. 2017 May 28;35(5):333-344. doi: 10.1080/07357907.2017.1289215. Epub 2017 Apr 3.

PMID:
28368708
8.

Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R, Murphy M, Morrell J, Beetsch J, Sargent DJ, Scher HI, Lebowitz P, Simon R, Stein WD, Bates SE, Fojo T.

Lancet Oncol. 2017 Jan;18(1):143-154. doi: 10.1016/S1470-2045(16)30633-7. Epub 2016 Dec 13.

PMID:
27979599
9.

Heterogeneity of Patients With Intermediate-Prognosis Metastatic Renal Cell Carcinoma Treated With Sunitinib.

Sella A, Michaelson MD, Matczak E, Simantov R, Lin X, Figlin RA.

Clin Genitourin Cancer. 2017 Apr;15(2):291-299.e1. doi: 10.1016/j.clgc.2016.08.013. Epub 2016 Aug 18.

PMID:
27638198
10.

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DYC, Choueiri TK.

J Clin Oncol. 2016 Oct 20;34(30):3655-3663. doi: 10.1200/JCO.2016.66.7311.

11.

Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.

Hamieh L, McKay RR, Lin X, Moreira RB, Simantov R, Choueiri TK.

Clin Genitourin Cancer. 2017 Apr;15(2):221-229. doi: 10.1016/j.clgc.2016.06.017. Epub 2016 Jun 29.

PMID:
27460432
12.

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.

Grünwald V, Lin X, Kalanovic D, Simantov R.

Eur Urol. 2016 Dec;70(6):1006-1015. doi: 10.1016/j.eururo.2016.05.010. Epub 2016 May 26.

PMID:
27238653
13.

Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy.

Templeton AJ, Knox JJ, Lin X, Simantov R, Xie W, Lawrence N, Broom R, Fay AP, Rini B, Donskov F, Bjarnason GA, Smoragiewicz M, Kollmannsberger C, Kanesvaran R, Alimohamed N, Hermanns T, Wells JC, Amir E, Choueiri TK, Heng DY.

Eur Urol. 2016 Aug;70(2):358-64. doi: 10.1016/j.eururo.2016.02.033. Epub 2016 Feb 28.

PMID:
26924770
14.

Statins and survival outcomes in patients with metastatic renal cell carcinoma.

McKay RR, Lin X, Albiges L, Fay AP, Kaymakcalan MD, Mickey SS, Ghoroghchian PP, Bhatt RS, Kaffenberger SD, Simantov R, Choueiri TK, Heng DY.

Eur J Cancer. 2016 Jan;52:155-62. doi: 10.1016/j.ejca.2015.10.008. Epub 2015 Dec 11.

PMID:
26687834
15.

Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma.

McKay RR, Rodriguez GE, Lin X, Kaymakcalan MD, Hamnvik OP, Sabbisetti VS, Bhatt RS, Simantov R, Choueiri TK.

Clin Cancer Res. 2015 Jun 1;21(11):2471-9. doi: 10.1158/1078-0432.CCR-14-2332. Epub 2015 Feb 27.

16.

Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma.

Grünwald V, McKay RR, Krajewski KM, Kalanovic D, Lin X, Perkins JJ, Simantov R, Choueiri TK.

Eur Urol. 2015 May;67(5):952-8. doi: 10.1016/j.eururo.2014.12.036. Epub 2015 Jan 7.

17.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L.

J Clin Oncol. 2014 Nov 10;32(32):3619-25. doi: 10.1200/JCO.2013.52.5683. Epub 2014 Sep 29.

PMID:
25267761
18.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma.

Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P.

J Clin Oncol. 2014 Nov 10;32(32):3659-66. doi: 10.1200/JCO.2013.54.8115. Epub 2014 Sep 29.

19.

A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors.

Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR.

Clin Cancer Res. 2015 Feb 15;21(4):701-11. doi: 10.1158/1078-0432.CCR-14-0303. Epub 2014 Sep 11.

20.

Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.

Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP.

Clin Cancer Res. 2015 Feb 15;21(4):693-700. doi: 10.1158/1078-0432.CCR-14-0265. Epub 2014 Sep 10.

21.

Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.

McKay RR, Lin X, Perkins JJ, Heng DY, Simantov R, Choueiri TK.

Eur Urol. 2014 Sep;66(3):502-9. doi: 10.1016/j.eururo.2014.02.040. Epub 2014 Feb 26.

22.

Comparison of central and intraesophageal factors between gastroesophageal reflux disease (GERD) patients and those with GERD-related noncardiac chest pain.

Shapiro M, Simantov R, Yair M, Leitman M, Blatt A, Scapa E, Broide E.

Dis Esophagus. 2012 Nov-Dec;25(8):702-8. doi: 10.1111/j.1442-2050.2011.01317.x. Epub 2012 Feb 6.

PMID:
22309285
23.

GPNMB expression in uveal melanoma: a potential for targeted therapy.

Williams MD, Esmaeli B, Soheili A, Simantov R, Gombos DS, Bedikian AY, Hwu P.

Melanoma Res. 2010 Jun;20(3):184-90. doi: 10.1097/CMR.0b013e3283364a08.

PMID:
20375921
24.

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.

Rose AA, Grosset AA, Dong Z, Russo C, Macdonald PA, Bertos NR, St-Pierre Y, Simantov R, Hallett M, Park M, Gaboury L, Siegel PM.

Clin Cancer Res. 2010 Apr 1;16(7):2147-56. doi: 10.1158/1078-0432.CCR-09-1611. Epub 2010 Mar 9.

25.

Amniotic stem cell international.

Simantov R.

Reprod Biomed Online. 2008 Apr;16(4):597-8.

PMID:
18413072
26.

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.

Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R.

Clin Cancer Res. 2007 May 1;13(9):2684-91.

27.

Sorafenib in advanced clear-cell renal-cell carcinoma.

Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM; TARGET Study Group.

N Engl J Med. 2007 Jan 11;356(2):125-34. Erratum in: N Engl J Med. 2007 Jul 12;357(2):203.

28.

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S.

Nat Rev Drug Discov. 2006 Oct;5(10):835-44. Review. Erratum in: Nat Rev Drug Discov. 2007 Feb;6(2):126.

PMID:
17016424
29.

Neprilysin inhibits angiogenesis via proteolysis of fibroblast growth factor-2.

Goodman OB Jr, Febbraio M, Simantov R, Zheng R, Shen R, Silverstein RL, Nanus DM.

J Biol Chem. 2006 Nov 3;281(44):33597-605. Epub 2006 Aug 28.

30.

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.

Eisen T, Ahmad T, Flaherty KT, Gore M, Kaye S, Marais R, Gibbens I, Hackett S, James M, Schuchter LM, Nathanson KL, Xia C, Simantov R, Schwartz B, Poulin-Costello M, O'Dwyer PJ, Ratain MJ.

Br J Cancer. 2006 Sep 4;95(5):581-6. Epub 2006 Aug 1.

31.

Aberrant accumulation of serotonin in dopaminergic neurons.

Mössner R, Simantov R, Marx A, Lesch KP, Seif I.

Neurosci Lett. 2006 Jun 19;401(1-2):49-54. Epub 2006 Apr 25.

PMID:
16638624
32.

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.

J Clin Oncol. 2006 Jun 1;24(16):2505-12. Epub 2006 Apr 24.

PMID:
16636341
33.

Stem cells may reshape the prospect of Parkinson's disease therapy.

Sonntag KC, Simantov R, Isacson O.

Brain Res Mol Brain Res. 2005 Mar 24;134(1):34-51. Review.

PMID:
15790528
34.

The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein.

Simantov R, Febbraio M, Silverstein RL.

Matrix Biol. 2005 Feb;24(1):27-34. Epub 2004 Dec 30.

PMID:
15748999
35.

Context-dependent neuronal differentiation and germ layer induction of Smad4-/- and Cripto-/- embryonic stem cells.

Sonntag KC, Simantov R, Björklund L, Cooper O, Pruszak J, Kowalke F, Gilmartin J, Ding J, Hu YP, Shen MM, Isacson O.

Mol Cell Neurosci. 2005 Mar;28(3):417-29.

PMID:
15737733
36.
37.

Temporally induced Nurr1 can induce a non-neuronal dopaminergic cell type in embryonic stem cell differentiation.

Sonntag KC, Simantov R, Kim KS, Isacson O.

Eur J Neurosci. 2004 Mar;19(5):1141-52.

38.

Genomic absence of the gene encoding T cell receptor Vbeta7.2 is linked to the presence of autoantibodies in Sjögren's syndrome.

Manavalan SJ, Valiando JR, Reeves WH, Arnett FC, Necker A, Simantov R, Lyons R, Satoh M, Posnett DN.

Arthritis Rheum. 2004 Jan;50(1):187-98.

39.

Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo.

Ling Q, Jacovina AT, Deora A, Febbraio M, Simantov R, Silverstein RL, Hempstead B, Mark WH, Hajjar KA.

J Clin Invest. 2004 Jan;113(1):38-48.

40.

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.

Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE.

N Engl J Med. 2003 Dec 18;349(25):2399-406. Erratum in: N Engl J Med. 2006 Oct 19;355(16):1746.

41.

Multiple molecular and neuropharmacological effects of MDMA (Ecstasy).

Simantov R.

Life Sci. 2004 Jan 2;74(7):803-14. Review.

PMID:
14659969
42.

CD36: a critical anti-angiogenic receptor.

Simantov R, Silverstein RL.

Front Biosci. 2003 Sep 1;8:s874-82. Review.

PMID:
12957861
44.

Synaptotagmin I and IV are differentially regulated in the brain by the recreational drug 3,4-methylenedioxymethamphetamine (MDMA).

Peng W, Premkumar A, Mossner R, Fukuda M, Lesch KP, Simantov R.

Brain Res Mol Brain Res. 2002 Dec;108(1-2):94-101.

PMID:
12480182
45.
46.
47.

Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease.

Mössner R, Henneberg A, Schmitt A, Syagailo YV, Grässle M, Hennig T, Simantov R, Gerlach M, Riederer P, Lesch KP.

Mol Psychiatry. 2001 May;6(3):350-2.

48.

Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice.

Pan Y, Gembom E, Peng W, Lesch KP, Mossner R, Simantov R.

Brain Res Dev Brain Res. 2001 Jan 31;126(1):125-9.

PMID:
11172895
49.

Histidine-rich glycoprotein inhibits the antiangiogenic effect of thrombospondin-1.

Simantov R, Febbraio M, Crombie R, Asch AS, Nachman RL, Silverstein RL.

J Clin Invest. 2001 Jan;107(1):45-52.

50.

Differential regulation of adenosine A(1) and A(2A) receptors in serotonin transporter and monoamine oxidase A-deficient mice.

Mössner R, Albert D, Persico AM, Hennig T, Bengel D, Holtmann B, Schmitt A, Keller F, Simantov R, Murphy D, Seif I, Deckert J, Lesch KP.

Eur Neuropsychopharmacol. 2000 Dec;10(6):489-93.

PMID:
11115739

Supplemental Content

Loading ...
Support Center